2022-09-012023-08-312023-08-31false12824276NEWCASTLE GYNAECOLOGY CLINIC LTD2023-10-0686220iso4217:GBPxbrli:pure128242762022-09-01128242762023-08-31128242762022-09-012023-08-31128242762021-09-01128242762022-08-31128242762021-09-012022-08-3112824276bus:SmallEntities2022-09-012023-08-3112824276bus:AuditExempt-NoAccountantsReport2022-09-012023-08-3112824276bus:AbridgedAccounts2022-09-012023-08-3112824276bus:PrivateLimitedCompanyLtd2022-09-012023-08-3112824276core:WithinOneYear2023-08-3112824276core:AfterOneYear2023-08-3112824276core:WithinOneYear2022-08-3112824276core:AfterOneYear2022-08-3112824276core:ShareCapital2023-08-3112824276core:SharePremium2023-08-3112824276core:RevaluationReserve2023-08-3112824276core:OtherReservesSubtotal2023-08-3112824276core:RetainedEarningsAccumulatedLosses2023-08-3112824276core:ShareCapital2022-08-3112824276core:SharePremium2022-08-3112824276core:RevaluationReserve2022-08-3112824276core:OtherReservesSubtotal2022-08-3112824276core:RetainedEarningsAccumulatedLosses2022-08-3112824276core:LandBuildings2023-08-3112824276core:PlantMachinery2023-08-3112824276core:Vehicles2023-08-3112824276core:FurnitureFittings2023-08-3112824276core:OfficeEquipment2023-08-3112824276core:NetGoodwill2023-08-3112824276core:IntangibleAssetsOtherThanGoodwill2023-08-3112824276core:ListedExchangeTraded2023-08-3112824276core:UnlistedNon-exchangeTraded2023-08-3112824276core:LandBuildings2022-08-3112824276core:PlantMachinery2022-08-3112824276core:Vehicles2022-08-3112824276core:FurnitureFittings2022-08-3112824276core:OfficeEquipment2022-08-3112824276core:NetGoodwill2022-08-3112824276core:IntangibleAssetsOtherThanGoodwill2022-08-3112824276core:ListedExchangeTraded2022-08-3112824276core:UnlistedNon-exchangeTraded2022-08-3112824276core:LandBuildings2022-09-012023-08-3112824276core:PlantMachinery2022-09-012023-08-3112824276core:Vehicles2022-09-012023-08-3112824276core:FurnitureFittings2022-09-012023-08-3112824276core:OfficeEquipment2022-09-012023-08-3112824276core:NetGoodwill2022-09-012023-08-3112824276core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3112824276core:ListedExchangeTraded2022-09-012023-08-3112824276core:UnlistedNon-exchangeTraded2022-09-012023-08-3112824276core:MoreThanFiveYears2022-09-012023-08-3112824276core:Non-currentFinancialInstruments2023-08-3112824276core:Non-currentFinancialInstruments2022-08-3112824276dpl:CostSales2022-09-012023-08-3112824276dpl:DistributionCosts2022-09-012023-08-3112824276dpl:AdministrativeExpenses2022-09-012023-08-3112824276core:LandBuildings2022-09-012023-08-3112824276core:PlantMachinery2022-09-012023-08-3112824276core:Vehicles2022-09-012023-08-3112824276core:FurnitureFittings2022-09-012023-08-3112824276core:OfficeEquipment2022-09-012023-08-3112824276core:NetGoodwill2022-09-012023-08-3112824276core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3112824276dpl:GroupUndertakings2022-09-012023-08-3112824276dpl:ParticipatingInterests2022-09-012023-08-3112824276dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3112824276core:ListedExchangeTraded2022-09-012023-08-3112824276dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3112824276core:UnlistedNon-exchangeTraded2022-09-012023-08-3112824276dpl:CostSales2021-09-012022-08-3112824276dpl:DistributionCosts2021-09-012022-08-3112824276dpl:AdministrativeExpenses2021-09-012022-08-3112824276core:LandBuildings2021-09-012022-08-3112824276core:PlantMachinery2021-09-012022-08-3112824276core:Vehicles2021-09-012022-08-3112824276core:FurnitureFittings2021-09-012022-08-3112824276core:OfficeEquipment2021-09-012022-08-3112824276core:NetGoodwill2021-09-012022-08-3112824276core:IntangibleAssetsOtherThanGoodwill2021-09-012022-08-3112824276dpl:GroupUndertakings2021-09-012022-08-3112824276dpl:ParticipatingInterests2021-09-012022-08-3112824276dpl:GroupUndertakingscore:ListedExchangeTraded2021-09-012022-08-3112824276core:ListedExchangeTraded2021-09-012022-08-3112824276dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-09-012022-08-3112824276core:UnlistedNon-exchangeTraded2021-09-012022-08-3112824276core:NetGoodwill2023-08-3112824276core:IntangibleAssetsOtherThanGoodwill2023-08-3112824276core:LandBuildings2023-08-3112824276core:PlantMachinery2023-08-3112824276core:Vehicles2023-08-3112824276core:FurnitureFittings2023-08-3112824276core:OfficeEquipment2023-08-3112824276core:AfterOneYear2023-08-3112824276core:WithinOneYear2023-08-3112824276core:ListedExchangeTraded2023-08-3112824276core:UnlistedNon-exchangeTraded2023-08-3112824276core:ShareCapital2023-08-3112824276core:SharePremium2023-08-3112824276core:RevaluationReserve2023-08-3112824276core:OtherReservesSubtotal2023-08-3112824276core:RetainedEarningsAccumulatedLosses2023-08-3112824276core:NetGoodwill2022-08-3112824276core:IntangibleAssetsOtherThanGoodwill2022-08-3112824276core:LandBuildings2022-08-3112824276core:PlantMachinery2022-08-3112824276core:Vehicles2022-08-3112824276core:FurnitureFittings2022-08-3112824276core:OfficeEquipment2022-08-3112824276core:AfterOneYear2022-08-3112824276core:WithinOneYear2022-08-3112824276core:ListedExchangeTraded2022-08-3112824276core:UnlistedNon-exchangeTraded2022-08-3112824276core:ShareCapital2022-08-3112824276core:SharePremium2022-08-3112824276core:RevaluationReserve2022-08-3112824276core:OtherReservesSubtotal2022-08-3112824276core:RetainedEarningsAccumulatedLosses2022-08-3112824276core:NetGoodwill2021-09-0112824276core:IntangibleAssetsOtherThanGoodwill2021-09-0112824276core:LandBuildings2021-09-0112824276core:PlantMachinery2021-09-0112824276core:Vehicles2021-09-0112824276core:FurnitureFittings2021-09-0112824276core:OfficeEquipment2021-09-0112824276core:AfterOneYear2021-09-0112824276core:WithinOneYear2021-09-0112824276core:ListedExchangeTraded2021-09-0112824276core:UnlistedNon-exchangeTraded2021-09-0112824276core:ShareCapital2021-09-0112824276core:SharePremium2021-09-0112824276core:RevaluationReserve2021-09-0112824276core:OtherReservesSubtotal2021-09-0112824276core:RetainedEarningsAccumulatedLosses2021-09-0112824276core:AfterOneYear2022-09-012023-08-3112824276core:WithinOneYear2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:CostValuation2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3112824276core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3112824276core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3112824276core:Non-currentFinancialInstrumentscore:CostValuation2022-08-3112824276core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-3112824276core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-3112824276bus:Director12022-09-012023-08-31

NEWCASTLE GYNAECOLOGY CLINIC LTD

Registered Number
12824276
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2023

NEWCASTLE GYNAECOLOGY CLINIC LTD
Company Information
for the year from 1 September 2022 to 31 August 2023

Director

RATNAVELU, Nithya, Dr

Registered Address

15 Riverside Studios Amethyst Road
Newcastle Business Park
Newcastle Upon Tyne
NE4 7YL

Registered Number

12824276 (England and Wales)
NEWCASTLE GYNAECOLOGY CLINIC LTD
Statement of Financial Position
31 August 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets5506880
506880
Current assets
Debtors64,000-
Cash at bank and on hand27,94622,738
31,94622,738
Creditors amounts falling due within one year7(7,912)(2,732)
Net current assets (liabilities)24,03420,006
Total assets less current liabilities24,54020,886
Creditors amounts falling due after one year8(6,737)(10,627)
Net assets17,80310,259
Capital and reserves
Called up share capital22
Profit and loss account17,80110,257
Shareholders' funds17,80310,259
The financial statements were approved and authorised for issue by the Director on 6 October 2023, and are signed on its behalf by:
RATNAVELU, Nithya, Dr
Director
Registered Company No. 12824276
NEWCASTLE GYNAECOLOGY CLINIC LTD
Notes to the Financial Statements
for the year ended 31 August 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Office Equipment4
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
4.Employee information

20232022
Average number of employees during the year00
5.Property, plant and equipment

Total

£
Cost or valuation
At 01 September 221,497
At 31 August 231,497
Depreciation and impairment
At 01 September 22617
Charge for year374
At 31 August 23991
Net book value
At 31 August 23506
At 31 August 22880
6.Debtors

2023

2022

££
Trade debtors / trade receivables4,000-
Total4,000-
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
7.Creditors within one year

2023

2022

££
Taxation and social security7,8072,635
Accrued liabilities and deferred income10597
Total7,9122,732
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
8.Creditors after one year

2023

2022

££
Amounts owed to related parties6,73710,627
Total6,73710,627